NCT06293430Not yet recruiting
Registry on Luma Vision's VERAFEYE System (ENLIgHT)
Registry on Luma Vision's VERAFEYE System in Catheter Ablation and Left Atrial Appendage Closure Procedures
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The objective of the study is to compile real-world data on the use of the VERAFEYE System in standard of care atrial fibrillation (AF) ablation procedures and left atrial appendage closure (LAAC) procedures.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 27 Feb 2024
- Start date
- 15 Dec 2027
- Primary completion date
- 15 Mar 2028
- Lead sponsor
- LUMA Vision Ltd.
- Diseases
- Atrial fibrillation
- NCT number
- NCT06293430
What you commit to
- Study type: Observational
- Planned participants: 50
- From 15 Dec 2027 to the primary completion date, 15 Mar 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who have undergone a previous cardiac ablation for the treatment of PAF/LAA Closure
- Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)
Other
- Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion
- Unrecovered/unresolved Adverse Events from any previous invasive procedure
- Subjects who are currently enrolled in another study (except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments)
Who the study is looking for
- Subject is 18 years of age or of legal age to give informed consent specific to state and national law at the time of consent
- Subjects is indicated for an atrial fibrillation ablation and/or a left atrial appendage closure procedure with the VERAFEYE System as navigation and imaging system, per physician discretion;
- Subject is able to understand and willing to provide written informed consent
- Subject is able and willing to complete all study assessments at an approved clinical investigational center
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.